Weekly OHDSI Digest - 25Sept2017

MauraBeaton · September 25, 2017, 6:47pm

OHDSI MEETINGS THIS WEEK

OHDSI Community Call - Tuesday at 12pm ET
https://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=811649.986822
US TOLL: +1-415-655-0001
Meeting Number: 199 982 907

Patient-level prediction (Eastern hemisphere) workgroup meeting - Wednesday at 3pm Hong Kong/Taiwan time
https://global.gotomeeting.com/join/9729176611

Population-Level Estimation (Western hemisphere) workgroup meeting - Thursday at 12pm ET
https://meetings.webex.com/collabs/#/meetings/detail?uuid=M3T9BZV9RSB6YNDM8WDDZMI19D-D1JL&occurrenceID=1501776000000

Hadoop WG meeting - Friday at 11am ET
WebEx: http://cloudera.webex.com/meet/sdolley

GIS working group meeting - Monday (October 2nd) at 10am ET
https://tufts.webex.com/mw3200/mywebex/default.do?service=1&siteurl=tufts&nomenu=true&main_url=%2Fmc3200%2Fe.do%3Fsiteurl%3Dtufts%26AT%3DMI%26EventID%3D562301137%26UID%3D528546812%26Host%3DQUhTSwAAAAT_EHuT3Ok-zHVhY1-kVGh78TH62dPsFk0x99qz1E9039sh_Eiepw8CoZeIF2SfnopQ8oAZaLN9PkzIZovRf2kV0%26FrameSet%3D2%26MTID%3Dm243d8e9a9c6c2d42d5182aeb5d30efdb1
Meeting Number: 735 317 239
Password: gaia

ANNOUNCEMENTS

2017 OHDSI Symposium Registration - Registration for this year’s symposium will be closing soon! Register here: https://www.ohdsi.org/symposium-registration/
PLEASE NOTE: Registration is for the main symposium only (set to take place on October 18th). Registration for tutorials is full.

Tutorial Registration - Tutorial registration is now closed and selected participants have been notified of their status. If you have registered for a tutorial but have not heard about your participant status, or if you would like to be placed on the waitlist, please email symposium@ohdsi.org

Call for Sponsorship - To fund the 2017 symposium we need to raise $200K to cover operating costs of venue rental, lunch, audio/visuals and recordings fees. We’re reaching out to the entire community for sponsors who want to support this important event and allow us to build upon the success of past symposia. More details: OHDSI Symposium 2017 - call for sponsorship

Updating OHDSI.org - Leading up to the symposium, we’ll be updating collaborator profiles and our data network list. If you have updates you’d like made to your OHDSI profile, or have updated information about your database, please email beaton@ohdsi.org with the changes.

We are all geniuses up to the age of ten.

Aldous Huxley

COMMUNITY PUBLICATIONS

Dynamic-ETL: a hybrid approach for health data extraction, transformation and loading

The representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0

Quality indicators and incentive programs for health care improvement.

Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers.

ncbi.nlm.nih.gov

Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers.

AG Winterstein, R Soria-Saucedo, T Gerhard, CU Correll and M Olfson, The Journal of clinical psychiatry, Jul 2017

To characterize treatment trajectories in children newly diagnosed with attention-deficit/hyperactivity disorder (ADHD).We utilized billing records of children aged 3 to 18 years in 28 US states' Medicaid programs between 1999 and 2006. Children entered the cohort at the first ADHD diagnosis (ICD-9-CM: 314.00) preceded by ≥ 6 months with no psychotropic medication use and no psychiatric diagnoses. We followed children for 5 years to assess use of (1) psychotropic polypharmacy (the use of ≥ 3 psychotropic medication classes), (2) antipsychotics, and (3) anticonvulsants. We used mixed-effects logistic regression to model the probability of each utilization outcome as a function of age at ADHD diagnosis and follow-up year, adjusted for sociodemographic factors.Our cohort included 16,626 children of whom 79.2% received stimulants, 33.2% antidepressants, and 23.1% α-agonists, and 25.3% received psychotropic polypharmacy treatment at least once in a subsequent year. Antipsychotics (7.1%-14.7%), anticonvulsants (4.0%-7.9%), and psychotropic polypharmacy (8.5%-13.4%) use increased from year 1 to 5, but this increase was confined to children between ages 3 and 9 at ADHD diagnosis. Children diagnosed at age 3 had the most substantial increase in each outcome (OR = 1.80 [95% CI, 1.36-2.38]; 1.85 [1.38-2.47]; 2.14 [1.45-3.16]), respectively. Also, 39.1% of 9,680 children-years with psychotropic polypharmacy therapy had no psychiatric diagnoses other than ADHD.Psychotropic polypharmacy, antipsychotic, and anticonvulsant use increased with each year of follow-up. This effect was strongly mediated by the age of ADHD diagnosis with substantial increases in preschoolers but no corresponding effect in older children. It was only partially explained by physician diagnoses of concomitant mental disorders.

The emergence and evolution of the research fronts in HIV/AIDS research.

ncbi.nlm.nih.gov

The emergence and evolution of the research fronts in HIV/AIDS research.

D Fajardo-Ortiz, M Lopez-Cervantes, L Duran, M Dumontier, M Lara, H Ochoa and VM Castano, PloS one, 2017

In this paper, we have identified and analyzed the emergence, structure and dynamics of the paradigmatic research fronts that established the fundamentals of the biomedical knowledge on HIV/AIDS. A search of papers with the identifiers "HIV/AIDS", "Human Immunodeficiency Virus", "HIV-1" and "Acquired Immunodeficiency Syndrome" in the Web of Science (Thomson Reuters), was carried out. A citation network of those papers was constructed. Then, a sub-network of the papers with the highest number of inter-citations (with a minimal in-degree of 28) was selected to perform a combination of network clustering and text mining to identify the paradigmatic research fronts and analyze their dynamics. Thirteen research fronts were identified in this sub-network. The biggest and oldest front is related to the clinical knowledge on the disease in the patient. Nine of the fronts are related to the study of specific molecular structures and mechanisms and two of these fronts are related to the development of drugs. The rest of the fronts are related to the study of the disease at the cellular level. Interestingly, the emergence of these fronts occurred in successive "waves" over the time which suggest a transition in the paradigmatic focus. The emergence and evolution of the biomedical fronts in HIV/AIDS research is explained not just by the partition of the problem in elements and interactions leading to increasingly specialized communities, but also by changes in the technological context of this health problem and the dramatic changes in the epidemiological reality of HIV/AIDS that occurred between 1993 and 1995.